# SAFETY DATA SHEET



### 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

**Product identifier** 

# XYLOCAINE SOLUTION FOR INJECTIONS

Details of the supplier of the safety data sheet

ASTRAZENECA PTY LTD 2 PO Box 131 Alma Road, North Ryde NSW 2113 **AUSTRALIA** +61 2 9978 3500

**Emergency Telephone** +44 (0) 1235 239 670

SafetyDataSheets.AlderleyPark@astrazeneca.com

#### **Alternative Names**

Lidocaine solution for injections

CAS No.	:	Not applicable
Use	:	Local anaesthetic solution for use in infiltration anaesthesia, intravenous regional
		anaesthesia and nerve blocks.

# 2. HAZARDS IDENTIFICATION

This mixture is not classified as hazardous for supply/use according to GHS v 4.0. May produce a reduced heart rate and reduction in blood pressure with a resulting feeling of dizziness.

# 3. COMPOSITION/INFORMATION ON INGREDIENTS

#### Mixture:

2	6108-05-0		
Hazard class <sup>#</sup>		Category	Hazard statements <sup>#</sup>
Acute toxicity		3	H301
2	lazard class <sup>#</sup>	6108-05-0	6108-05-0 lazard class <sup>#</sup> Category

# Refer to Section 16 'Other Information

#### **4. FIRST-AID MEASURES**

#### Description of first aid measures

Inhalation Remove patient from exposure. Obtain medical attention if ill effects occur. :

- Wash skin with soap and water. Skin Contact
- Eye Contact Irrigate with eyewash solution or clean water, holding the eyelids apart, for at least 10 : minutes. Obtain medical attention if ill effects remain.
  - Wash out mouth with water and give 200-300ml of water to drink. Obtain medical attention 2 if ill effects occur. Do NOT induce vomiting as a First-Aid measure.

#### Most important symptoms and effects, both acute and delayed

Refer to sections 2 and 11

#### Indication of any immediate medical attention and special treatment needed

Symptomatic treatment and supportive therapy as indicated. For further detail consult the prescribing information.

Page 1 of 5

Ingestion

Revision : 19.02.2014 Version: 1.0

Extinguishing Media (suitable) Extinguishing Media (unsuitable)	:	water spray, foam, dry powder or CO2. -
Special hazards arising from the substance or mixture	:	If involved in a fire, it may emit noxious and toxic fumes.
Special protective actions for fire-fighters	:	A self contained breathing apparatus and suitable protective clothing should be worn in fire conditions.

# 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	:	Ensure suitable personal protection during removal of spillages. See Section 8. Ensure adequate ventilation.
Environmental Precautions	:	Prevent entry into drains.
Methods and material for containment and cleaning up	:	Clear up spillages. Wash the spillage area with water. Transfer spilled vials to a suitable container for disposal.
7. HANDLING AND STORAGE		

Precautions for safe handling Conditions for safe storage, including any incompatibilities	:	Avoid contact with skin and eyes. Avoid inhalation of vapour/mist. Keep container tightly closed. Protect from light. Do not freeze.	
Specific end use(s)	:	Storage temperature : < 25 °C Not applicable, refer to Section 1	

# 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### **Control parameters**

#### **Occupational Exposure Limit Value**

Components	Value	Control parameters	Comments
Lidocaine hydrochloride	1 mg/m3	LTEL 8hr TWA	COM
Lidocaine hydrochloride	5 mg/m3	STEL 15min	COM

#### **Exposure Controls**

The specific controls will depend on local circumstances and should be based on the risk assessment. Appropriate controls to reduce exposure may include engineering controls, for example ventilation, procedural controls and the use of personal protection equipment.

Prevent entry into drains, sewers or watercourses.

#### Occupational exposure controls

Decisions about whether the use of personal protective equipment (PPE) is appropriate as part of the control strategy should be based on the workplace risk assessment and should take account of local legislative requirements for selection and use. There are multiple factors that will affect the specific requirements such as amount and concentration of the material, duration of exposure, frequency of exposure, external environmental conditions, the task, the user etc.

The information below should not be used in isolation and should be considered in the context of the workplace risk assessment on a case by case basis.

The recommended personal protective equipment (PPE) is based on preventing the potential adverse health effects from exposure to the active pharmaceutical ingredient (API). The risk of exposure to the API in the formulation/product needs to be taken into consideration.

#### **Respiratory protection**

Use a negative pressure air purifying respirator (half face mask) with filter class A if the risk assessment does not support the selection of other protection.

#### Skin protection

Avoid contact with skin. Use chemical protective gloves with a permeation time greater than the activity duration. Take note of the information given by the PPE producer/supplier concerning permeability and breakthrough times and special workplace conditions.

#### Eye protection

Use safety glasses to protect against direct contact with the product if the risk assessment does not support the selection of other protection.

# 9. PHYSICAL AND CHEMICAL PROPERTIES

#### Information on basic physical and chemical properties

:	liauid
:	clear aqueous solution
:	odourless
:	6,5
:	100 °C approx
:	17 mmHg 20 °C
:	soluble
:	1,00 approx
:	0,600
	:

Other information

No other data available

# **10. STABILITY AND REACTIVITY**

Reactivity	:	No known reactivity hazard under normal conditions.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	None known.
Conditions to avoid	:	No conditions producing hazardous situations known.
Incompatible materials	:	None known.
Hazardous decomposition products	:	No hazardous decomposition products are known.

# **11. TOXICOLOGICAL INFORMATION**

The following information refers to Lidocaine hydrochloride: The following health hazard assessment is based on a consideration of the composition of this product.

Inhalation	:	No information available on acute toxicity. May cause effects as described under single exposure.(STOT)
Skin Contact	:	May cause numbness.
Eye Contact	:	May cause excessive watering of the eye (lachrymation).
Ingestion	:	Harmful if swallowed. Oral Median Lethal Dose (rat) 159 - 324 mg/kg May cause effects as described under single exposure.(STOT)
Specific Target Organ Toxicity (STOT)	:	<b>Single exposure</b> Exposure routes: Inhalation High atmospheric concentrations may lead to anaesthetic effects., May produce a reduced heart rate and reduction in blood pressure with a resulting feeling of dizziness.
		Exposure routes: Oral
Page 3 of 5		Revision - 19.02.2014

		May produce numbness of the tongue and anaesthetic effects on the stomach.
		<b>Repeated exposure</b> Repeated exposure of animals to high levels produces adverse effects on the liver and central nervous system.
Sensitisation	:	Repeated and/or prolonged contact may cause skin sensitisation in a small proportion of sensitive individuals.
Carcinogenicity	:	No information available on this substance.
Mutagenicity	:	The substance is not considered to be genotoxic.
Reproductive toxicity	:	There is no evidence of teratogenicity or embryotoxicity.

# **12. ECOLOGICAL INFORMATION**

The following information refers to active ingredient:

Toxicity	:	Low toxicity to aquatic organisms. EC50 green algae 72 H 780 mg/l EC50 Daphnia magna 48 H 112 mg/l LC50 Zebra Fish 96 H 106 mg/l LC50 (microtox test) 15 MIN > 1 000 mg/l		
Effect on Effluent Treatment	:	No information available.		
Persistence and degradability	:	Not rapidly degradable.		
Bioaccumulative potential		The substance has low potential for bioaccumulation.		
Mobility in soil	:	Water solubility >= 1 mg/l.		
Other adverse effects		No information available.		

# **13. DISPOSAL CONSIDERATIONS**

Waste treatment methods	:	Disposal should be in accordance with local, state or national legislation.

Contaminated Packaging :		Empty container will retain residue.	Obse	rve all h	azard	precautions.
--------------------------	--	--------------------------------------	------	-----------	-------	--------------

# **14. TRANSPORT INFORMATION**

NOT RESTRICTED FOR TRANSPORT

# **15. REGULATORY INFORMATION**

In order to comply with legal duties it is necessary to consult local and national legislation.

#### **16. OTHER INFORMATION**

Hazard statements

H301 : Toxic if swallowed.

The following sections contain revisions or new statements :

The Safety Data Sheet has been updated to adhere to Globally Harmonized System of Classification and Labelling of Chemicals (GHS)., This update affects most Sections of the Safety Data Sheet.

GLOSSARY		
COM	:	In-house occupational exposure limit
LTEL	:	Long-term exposure limit (8 hour TWA (time-weighted average))
STEL	:	Short-term exposure limit (15-minute TWA (time-weighted average))
TLV	:	Threshold Limit Value (ACGIH)
TLV-C	:	Threshold Limit Value - Ceiling limit (ACGIH)
HYG	:	An in-house analytical method for occupational exposure monitoring is available
Sk	:	Can be absorbed through skin, thus contributing to systemic effects
Sen	:	Capable of causing respiratory sensitisation

This Glossary is applicable to Substances for which Hazardous Ingredients/Occupational Exposure Limits are assigned.